Clinical trials: Hospitalized COVID-19
Paxlovid, Azvudine
Evaluation of the Safety and Efficacy of Azvudine and Paxlovid in the Treatment of Hospitalized Patients With COVID-19
In this retrospective study, we aimed to evaluate the clinical efficacy and safety of two antiviral drugs on COVID-19 and inpatients with existing complications in the First Affiliated Hospital of Shandong First Medical…
- Conditions
- Paxlovid, Azvudine, COVID-19
- Trial name
- NCT05996770
- Volunteers
- 1,500 people
- Sponsor
- Xiao Li，MD
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
covid19
Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19
This is a pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BID compared to placebo to treat hospitalized patients with non-critical COVID-19.
- Trial name
- NCT04423861
- Testing
- Nitazoxanide
- Where
- Brazil
- Volunteers
- 380 people
- Sponsor
- Azidus Brasil
COVID-19
Coronavirus Disease 2019 (COVID-19) Antibody Plasma Research Study in Hospitalized Patients
The purpose of this research study is to find out if CCP is safe and to determine the safest and most effective level of anti-viral antibody when given to people admitted to the hospital with confirmed COVID-19 infection.
- Trial name
- UNC CCP RCT (NCT04524507)
- Testing
- High-titer Convalescent COVID-19 Plasma (CCP1), Standard-titer Convalescent COVID-19 plasma (CCP2)
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of North Carolina, Chapel Hill
Covid-19
Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia
The aim of the research is to improve patient management by rapidly identifying, based on the terrain and clinical and biological characteristics, those patients likely to present a severe form of ARDS at risk of leading to…
- Trial name
- NCT04362345
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Pneumonia, COVID-19
Clinical, Virological, Serological and Immunological Characteristics During and Following COVID-19 Hospitalization
Assessment of the association between the severity of COVID-19 and SARS-CoV-2 NAb titers levels for up to six months following primary infection using a live virus NAb assay.
- Trial name
- COVISERA (NCT05274373)
- Where
- Denmark
- Volunteers
- 47 people
- Sponsor
- Nordsjaellands Hospital
Covid19, Diabetes Mellitus
The Effect of Diabetes Mellitus on Mortality of Patients With COVID-19
The study includes patients over 18 years old who were hospitalized in our covid intensive care unit between March 16 and May 16, 2020. Retrospective records were examined by examining the electronic data files of the patients.
- Trial name
- NCT04663659
- Testing
- no intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
COVID-19, Mental Health
Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark
Background: There is limited knowledge on the psychological implications of COVID-19 among hospitalized patients and their close relatives.
- Conditions
- COVID-19, Mental Health, Psychoeducation, Anxiety
- Trial name
- PISCA (NCT04351789)
- Testing
- Psychoeducational intervention
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Tocilizumab for Patients With Cancer and COVID-19 Disease
This phase II expanded access trial will study how well tocilizumab works in reducing the serious symptoms including pneumonitis (severe acute respiratory distress) in patients with cancer and COVID-19.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis
- Trial name
- NCT04370834
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Psychiatric Hospitalization
Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic
Subjects will be recently discharged patients from Sunnybrook Inpatient Psychiatry Unit. Subjects will be randomized in a 1:1 ratio to either the Caring Contact intervention or usual care.
- Trial name
- NCT04456062
- Testing
- Caring Contacts
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Sunnybrook Health Sciences Centre
COVID-19
A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.
- Trial name
- NCT05442983
- Testing
- PanCytoVir™ (probenecid)
- Where
- India
- Volunteers
- 75 people
- Sponsor
- TrippBio, Inc.
COVID-19
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants
- Trial name
- NCT04784897
- Testing
- Brilacidin, Standard of Care (SoC)
- Where
- 12 sites in United States, Russia
- Volunteers
- 120 people
- Sponsor
- Innovation Pharmaceuticals, Inc.
Covid19, Inflammation
Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most…
- Trial name
- BeeCovid2 (NCT04800224)
- Testing
- Standardized Brazilian Green Propolis Extract
- Where
- Brazil
- Volunteers
- 200 people
- Sponsor
- D'Or Institute for Research and Education
Coronavirus Disease 2019 (COVID-19)
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection
The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in…
- Trial name
- PREVENT-HD (NCT04508023)
- Testing
- Rivaroxaban, Standard of Care (SOC)
- Where
- 17 sites in United States
- Volunteers
- 1,284 people
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras
This is a single-arm, open-label, phase II clinical study to evaluate the safety and efficacy of thymic peptides in the treatment of hospitalized COVID-19 patients in Honduras.
- Trial name
- NCT04771013
- Testing
- Thymic peptides
- Where
- Honduras
- Volunteers
- 22 people
- Sponsor
- Universidad Católica de Honduras
Covid19, Kidney Diseases
Michigan Medicine COVID-19 Cohort: Clinical Characteristics, Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with…
- Conditions
- Covid19, Kidney Diseases, Inflammation, SARS-CoV Infection
- Trial name
- M2C2 (NCT04706533)
- Testing
- Biomarkers of inflammation
- Where
- United States
- Volunteers
- 3,402 people
- Sponsor
- University of Michigan
Acute Respiratory Distress Syndrome
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
The purpose of this study was to evaluate the efficacy and safety of poractant alfa (Curosurf®), administered by endotracheal (ET) instillation in hospitalized adult patients diagnosed with SARS-COV-19 acute respiratory distress…
- Trial name
- NCT04502433
- Testing
- CUROSURF® (poractant alfa)
- Where
- 6 sites in United States, Italy and 1 more
- Volunteers
- 22 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Covid19
Study of ZnAg Liquid Solution to Treat COVID-19 Symptomatic Participants
This is a multi-site, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of ZnAg liquid solution in symptomatic participants with acute COVID-19 that are not hospitalized at the time of…
- Trial name
- NCT04610138
- Testing
- CNM-ZnAg
- Where
- 5 sites in Brazil
- Volunteers
- 296 people
- Sponsor
- Clene Nanomedicine
COVID-19, Pneumonia
Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia
To assess the clinical efficacy of ANG-3777 relative to the standard of care in reducing the severity and progression of pulmonary and renal dysfunction and mortality in adult patients hospitalized with COVID-19 pneumonia
- Trial name
- NCT04459676
- Testing
- Standard of Care (SOC) + ANG-3777
- Where
- 10 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Angion Biomedica Corp